CClinicalTrials.gg
CompletedNCT04967885Updated Apr 24, 2023Results posted

Ecological Momentary Intervention of Implementation Intentions Delivered by Text Message to Reduce Cigarette Smoking

An interventional study of Ecological Momentary Implementation Intentions Intervention (EMI-II) in Cigarette Smoking, sponsored by Trustees of Dartmouth College. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-04-24.

Sponsored by Trustees of Dartmouth College · Not applicable, Interventional, and Supportive care

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study will develop an ecological momentary implementation intentions intervention (EMI-II) for cigarette smoking, which will link critical situations where smoking is likely to occur with alternative responses to support avoidance of cigarette use. Using ecological momentary assessment (EMA) for data collection, this project will evaluate the feasibility, acceptability, and initial effectiveness of a micro-randomized trial (MRT) of EMI-II targeting cigarette smoking reduction in a sample of adults who smoke a minimum of 15 cigarettes per day (n=100).

Read the detailed description

Cigarette smoking accounts for nearly 1 in 5 preventable deaths in the United States, and reducing cigarette smoking has been suggested for those not yet ready to quit. Cigarette reduction has been shown to longitudinally predict eventual cessation. Evidence suggests that smoking is highly sensitive to environmental stimuli, so ecological momentary interventions (EMI) embedded within daily life may help reduce cigarette smoking. Within the context of EMIs, researchers have explored different strategies to support smoking cessation and reduction. Implementation interventions (II) is a novel self-regulatory strategy that may help individuals reduce smoking. In II, individuals identify critical situations where smoking is likely to occur, then develop and plan appropriate alternative responses to avoid cigarette use. When II is delivered as a brief, single session intervention, II increases cessation rates relative to control conditions. Although II is well-suited for EMI because the brief messages are designed to be contextually relevant, no known research has evaluated whether repeated administration of II delivered by EMI reduces cigarette use. EMI-II may be beneficial with greater exposure and when delivered in the contexts where a behavior, such as smoking, is likely to occur.

This randomized controlled trial aims to test an ecological momentary implementation intentions intervention (EMI-II) to reduce cigarette smoking. This research seeks to identify in-the-moment intervention components that target momentary contextual and personal variables to effectively reduce cigarette smoking. Adults who smoke and are interested in reducing their cigarette use will be randomized to either the immediate intervention condition, or to a waitlist control. All participants will be followed for one month and will complete weekly surveys. Intervention participants will receive two weeks of the EMI-II with daily ecological momentary assessments (EMAs) in the two weeks post-randomization. Waitlist control participants will complete the weekly surveys for two weeks, then have access to the EMI-II with daily EMAs for two weeks. The daily EMAs are brief surveys in which participants report their current context and recent behavior and events.

This project consists of two primary aims:

Aim 1. To test the feasibility and acceptability of a customized, micro-randomized trial using EMI-II for smoking reduction.

The investigators hypothesize that at least 75% of participants who start the EMI-II component will complete the two-week active study period. Also, the investigators hypothesize that participants will rate the acceptability of the EMI-II at least a 3.5 out of 5, on average.

Aim 2. Test the initial effectiveness of EMI-II for reducing cigarette smoking.

The investigators hypothesize that participants receiving EMI-II will show greater reductions in self-reported smoking than participants assigned to an EMA-only control. In addition, the investigators hypothesize that self-reported cigarette smoking during the next EMA following EMI-II presentation will be lower, relative to cigarette smoking reported in EMAs that do not proximally follow the EMI-II delivery.

02

Conditions studied

  • Cigarette Smoking

Keywords

  • Ecological Momentary Assessment
  • mHealth
  • Smoking
  • Implementation Intentions
03

In context

Lead sponsor

Trustees of Dartmouth College is the lead sponsor of 38 studies on the registry; 18 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • 18 years of age or older
  • English-language proficient
  • Located in the United States
  • Self-reports smoking 15 or more cigarettes per day in the past week
  • Expresses interest in quitting or reducing smoking
  • Has a cell phone with access to text messaging
  • Willing to send and receive text messages related to smoking

Exclusion criteria

Exclusion Criteria:

  • Currently pregnant or plans to become pregnant
  • Currently on psychotropic medications for smoking cessation
  • Currently receiving behavioral treatment/therapy for smoking cessation
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
80 participants (actual)

Study arms

  • Experimental
    Immediate Intervention

    Participants in the Immediate Intervention condition will create their Implementation Intention (II) messages before the two-week EMA + EMI-II period begins. During the EMA + EMI-II period, participants will complete five daily EMAs, and they will also complete weekly assessments reporting their past week cigarette smoking as a distal outcome and rating intervention acceptability. Following the EMA + EMI-II period, participants will enter a two-week follow-up period. During this time, participants will not receive any messages, but will report past week smoking on a weekly basis.

    Behavioral: Ecological Momentary Implementation Intentions Intervention (EMI-II)

  • Active comparator
    Waitlist

    Participants randomized to the Waitlist control condition will begin with a two-week no intervention condition during which they will report past week smoking on a weekly basis but will not receive any other intervention components. At the end of the two-week waitlist control period, participants will begin the two-week EMA plus EMI-II period. During the EMA plus EMI-II active study period, participants will complete five daily EMAs and weekly assessments to report their past week cigarette smoking and rate intervention acceptability. No follow-up is planned for the wait list control condition.

    Behavioral: Ecological Momentary Implementation Intentions Intervention (EMI-II)

Interventions

  • BehavioralEcological Momentary Implementation Intentions Intervention (EMI-II)

    To reduce smoking, this text messaging intervention will use a self-regulatory strategy, Implementation Intentions (II) to deliver appropriate alternative responses to cigarette smoking. Participants will create personalized II messages before starting the two-week intervention period. Then during the intervention period, after receiving Ecological Momentary Assessments (EMAs), participants will be micro-randomized to receive the EMI-II. During the EMA + EMI-II period, participants will complete five daily EMAs. After approximately 40% of these EMAs, participants will also receive the personalized EMI-II by text messaging.

06

What researchers measure

Primary outcomes

  1. Percent of Participants Completing Intervention Period

    To evaluate the feasibility of this customized EMI-II intervention, the investigators will examine the proportion of study participants completing the two-week intervention period, Week 2 in the Immediate Intervention arm and week 4 in the Waitlist arm.

    Time frame: 2 weeks

  2. Average Acceptability of the EMI-II Intervention

    To examine the acceptability of the EMI-II intervention, participants will rate the acceptability of the intervention on a Likert scale ranging from 1 (low acceptability) to 5 (high acceptability) on the two weekly surveys completed during the intervention period.

    Time frame: 2 weeks

  3. Rate of Self-reported Cigarette Smoking

    Self-reported cigarette smoking will be assessed five times per day (morning, late morning, early afternoon, late afternoon, evening) during the intervention period. Participants will respond via text messaging to the question, "Since the last prompt, how many cigarettes have you smoked?"

    Time frame: 2 weeks

07

Results

Posted Mar 27, 2023
Limitations and caveats
More than twenty percent of participants were lost to follow-up before completing the final study survey.

Participant flow

Week 1 Follow-Up
Participant flow — Week 1 Follow-Up
MilestoneImmediate InterventionWaitlist
Started3941
Completed3237
Not completed74
Withdrew: Lost to follow-up74
Week 2 Follow-Up
Participant flow — Week 2 Follow-Up
MilestoneImmediate InterventionWaitlist
Started3941
Completed2535
Not completed146
Withdrew: Lost to follow-up146
Week 3 Follow-Up
Participant flow — Week 3 Follow-Up
MilestoneImmediate InterventionWaitlist
Started3941
Completed2330
Not completed1611
Withdrew: Lost to follow-up1611
Week 4 Follow-Up
Participant flow — Week 4 Follow-Up
MilestoneImmediate InterventionWaitlist
Started3941
Completed2331
Not completed1610
Withdrew: Lost to follow-up1610
EMI-II Intervention
Participant flow — EMI-II Intervention
MilestoneImmediate InterventionWaitlist
Started3941
Completed2531
Not completed1410
Withdrew: Lost to follow-up1410

Outcome measures

PrimaryPercent of Participants Completing Intervention Period

To evaluate the feasibility of this customized EMI-II intervention, the investigators will examine the proportion of study participants completing the two-week intervention period, Week 2 in the Immediate Intervention arm and week 4 in the Waitlist arm.

Time frame:
2 weeks
Reported as:
Count of participants · Participants
Percent of Participants Completing Intervention Period
ParticipantsImmediate InterventionWaitlist
Percent of Participants Completing Intervention Period2531
PrimaryAverage Acceptability of the EMI-II Intervention

To examine the acceptability of the EMI-II intervention, participants will rate the acceptability of the intervention on a Likert scale ranging from 1 (low acceptability) to 5 (high acceptability) on the two weekly surveys completed during the intervention period.

Time frame:
2 weeks
Reported as:
Mean · score on a scale
Average Acceptability of the EMI-II Intervention
score on a scaleImmediate InterventionWaitlist
Average Acceptability of the EMI-II Intervention3.85 ± 0.843.55 ± 0.97
Statistical analysis
  • Immediate Intervention vs Waitlist · t-test, 2 sided · p = 0.24
PrimaryRate of Self-reported Cigarette Smoking

Self-reported cigarette smoking will be assessed five times per day (morning, late morning, early afternoon, late afternoon, evening) during the intervention period. Participants will respond via text messaging to the question, "Since the last prompt, how many cigarettes have you smoked?"

Time frame:
2 weeks
Reported as:
Mean · cigarettes smoked per day
Rate of Self-reported Cigarette Smoking
cigarettes smoked per dayImmediate InterventionWaitlist
Rate of Self-reported Cigarette Smoking30.3 ± 7.130.1 ± 5.0

Adverse events

Collected over 1 month. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Immediate Intervention0/39 (0%)0/39 (0%)0/39 (0%)
Waitlist0/41 (0%)0/41 (0%)0/41 (0%)

Baseline characteristics

Participants

Age, Continuous
Age, Continuous(years)Immediate InterventionWaitlistTotal
Mean42.6 ± 1.540.0 ± 1.741.3 ± 1.1
Sex: Female, Male
Sex: Female, Male(Participants)Immediate InterventionWaitlistTotal
Female312455
Male81725
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Immediate InterventionWaitlistTotal
Hispanic or Latino235
Not Hispanic or Latino373875
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Immediate InterventionWaitlistTotal
American Indian or Alaska Native055
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American516
White333366
More than one race123
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)Immediate InterventionWaitlistTotal
United States394180
Cigarettes smoker per day
Cigarettes smoker per day(cigarettes smoked per day)Immediate InterventionWaitlistTotal
Mean30.2 ± 5.830.3 ± 7.230.2 ± 6.4
08

Study locations

1 site
  • Center for Technology and Behavioral Health, Dartmouth College
    Lebanon, New Hampshire 03766, United States
09

References and documents

Study documents

  • Protocol and statistical analysis plan · Sep 22, 2021

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 24, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04967885
Lead sponsor
Trustees of Dartmouth College
Collaborators
National Institute on Drug Abuse (NIDA)
Responsible party
Sponsor
First posted
Jul 20, 2021
Start date
Jun 8, 2021
Primary completion
Dec 31, 2021
Completion
Dec 31, 2021
Results posted
Mar 27, 2023
Last update
Apr 24, 2023

Study contacts

Elizabeth C Saunders, PhD
principal investigator · Dartmouth College

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion